Who
Eric Warren
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Mineralys Therapeutics; Chief Commercial Officer, Esperion Therapeutics.
In numbers
- Trades disclosed
- 59
- Buys
- 1
- Sells
- 30
- Bought
- $7,460
- Sold
- $6.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 14 Mar 2022
- Last trade
- 21 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Sep 2026filed 22 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $98K7,438 at $13.24 | filing |
| 21 Sep 2026filed 22 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $209K7,438 at $28.12 | filing |
| 21 Sep 2026filed 22 Sep 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,438 at $0.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,438 at $0.00 | filing |
| 21 Sep 2026filed 22 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $98K7,438 at $13.24 | filing |
| 21 Sep 2026filed 22 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $209K7,438 at $28.12 | filing |
| 21 Aug 2026filed 25 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $98K7,437 at $13.24 | filing |
| 21 Aug 2026filed 25 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $193K7,437 at $25.98 | filing |
| 21 Aug 2026filed 25 Aug 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,437 at $0.00 | filing |
| 21 Aug 2026filed 25 Aug 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,437 at $0.00 | filing |
| 21 Aug 2026filed 25 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $98K7,437 at $13.24 | filing |
| 21 Aug 2026filed 25 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $193K7,437 at $25.98 | filing |
| 21 Jul 2026filed 23 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $98K7,438 at $13.24 | filing |
| 21 Jul 2026filed 23 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $200K7,438 at $26.87 | filing |
| 21 Jul 2026filed 23 Jul 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,438 at $0.00 | filing |
| 21 Jul 2026filed 23 Jul 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,438 at $0.00 | filing |
| 21 Jul 2026filed 23 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $98K7,438 at $13.24 | filing |
| 21 Jul 2026filed 23 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $200K7,438 at $26.87 | filing |
| 26 Jun 2026filed 30 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.4M104,124 at $13.24 | filing |
| 26 Jun 2026filed 30 Jun 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.7M104,124 at $25.90 | filing |
News
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026MLYS · manilatimes.net · 22 Oct 2026Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsMLYS · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Eric Warren; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.